Skip to content

Study · Non-randomized trial · 2025

4 results

Systemic davunetide provides sex-specific neuroprotection during Coronary Artery Bypass Grafting (CABG).

Gozes I, Blatt J, Guz LS

Translational psychiatry31 Oct 2025Cited by 5 (Europe PMC)

PMID41173865 (opens in a new tab)PMCIDPMC12578781 (opens in a new tab)DOI10.1038/s41398-025-03675-y (opens in a new tab)PepBankPUB-41173865
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In men undergoing CABG, intravenous davunetide showed potential dose-dependent accumulation over time.

    In plain wordsIn men undergoing heart bypass surgery, intravenous davunetide potentially accumulated with dose over time.

    Peptide
    Davunetide
    Outcome
    IncreaseDrug accumulation in men
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    we implicated, for the first time, a differential drug metabolism/bioavailability between men and women, with a potential dose-dependent accumulation in men and an opposite decline/no concentration change in women over time.
  2. 02HumanNon-randomized trialPharmacokinetics

    In women undergoing CABG, intravenous davunetide showed a decline or no concentration change over time.

    In plain wordsIn women undergoing heart bypass surgery, intravenous davunetide concentrations declined or did not change over time.

    Peptide
    Davunetide
    Outcome
    MixedConcentration change in women
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    we implicated, for the first time, a differential drug metabolism/bioavailability between men and women, with a potential dose-dependent accumulation in men and an opposite decline/no concentration change in women over time.
  3. 03HumanNon-randomized trialEfficacy outcome

    In CABG patients, davunetide findings were linked with apparent protection against brain cell death or disease progression based on blood NSE.

    In plain wordsIn heart bypass patients, davunetide findings suggested protection against brain cell death or disease progression based on blood NSE.

    Peptide
    Davunetide
    Outcome
    Direction not reportedNSE-linked neuroprotection
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    These findings, while requiring caution due to the small cohort size, were linked with an apparent protection against brain cell death/disease progression by davunetide (AL-208) neuroprotective effects (neuron-specific enolase - NSE blood content).
  4. 04HumanNon-randomized trialEfficacy outcome

    In men undergoing CABG, davunetide increased cognitive function versus placebo in the Verbal Paired Associates II test.

    In plain wordsIn men undergoing heart bypass surgery, davunetide improved Verbal Paired Associates II performance compared with placebo.

    Peptide
    Davunetide
    Outcome
    IncreaseVerbal Paired Associates II versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    In men, also for the first time under these circumstances, neuroprotection was coupled to cognitive function increases in the treated group versus placebo, reaching healthy control levels in the Verbal Paired Associates II test,

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT00404014

Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

Allon Therapeuticsn = 234Aug 2006 to Jun 2008

Mild Cognitive Impairment

Trial pageClinicalTrials.govUpdated 24 Oct 2012

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.